PYC Therapeutics Ltd’s latest earnings call for the second quarter of 2025 highlighted the company’s strategic focus on pipeline development and potential asset monetization. Despite no specific ...

It also covers the PD-1+ NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in the PD-1 ...

This story was excerpted from Keegan Matheson’s Blue Jays Beat newsletter. To read the full newsletter, click here. And subscribe to get it regularly in your inbox. TORONTO -- Buffalo is getting ...

City Therapeutics is a biopharmaceutical company harnessing next-generation engineering of RNAi trigger molecules to improve and expand the reach of RNAi-based medicines. The company is building a ...

INDIANAPOLIS, IN, USA I May 27, 2025 I Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. (“SiteOne ... Target or technology pipeline and corporate benchmark analysis and assessment ...

It covers the Meningioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Meningioma pipeline therapeutics assessment by product type, stage ...

US pharma major Eli Lilly (NYSE: LLY) has announced a definitive agreement to acquire SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to ...

Investing.com -- Eli Lilly and Company (NYSE:LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a deal worth up to $1 billion, deepening its bet on non ...

INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of ...